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The efficacy of atovaquone (ATO) combined with clindamycin (CLI) against Toxoplasma gondii
was examined in murine models of infection with a mouse-non-virulent (Me49) strain. Swiss-
Webster mice inoculated by mouth with 10 or 20 cysts were treated with ATO and CLI alone or
combined at dosages of ATO 5–100 and CLI 25–400 mg/kg/day for 2–4 weeks. Drug treatment
was initiated (i) day 4 post-infection (acute infection), (ii) 3 months post-infection (chronic
infection) and (iii) following a 2–3 week course of treatment with dexamethasone (DXM) alone or
combined with cortisone-acetate (CA) introduced 3 months post-infection (reactivated toxo-
plasmosis). In acute infection, whereas treatment with any drug or drug combination signific-
antly enhanced survival and reduced the brain cyst burden, in mice treated with ATO alone or
combined with CLI, the cyst counts were significantly lower than in mice treated with CLI alone.
In chronic infection, the decrease in the cyst burden observed 2 weeks after treatment with either
drug alone was significant only in mice treated with the combined drugs. Most importantly, in
reactivated toxoplasmosis, whereas an effect for the combined drugs was shown in mice
suppressed with both DXM alone and combined with CA, in mice pre-treated with DXM a 3 week
course of ATO ≥25 and CLI 50 mg/kg/day significantly increased survival and markedly
decreased the cyst burden. The latter effect was long-term, since the cyst burdens in treated
mice continued to decrease up to 3 months later, whereas they increased in the untreated mice.
The results warrant clinical evaluation of the combination of ATO and CLI in the treatment of toxo-
plasmosis in both immunocompetent and, more importantly, immunosuppressed patients.
Introduction
The AIDS pandemic and the use of intensive immuno-
suppressive therapies for a variety of conditions, including
before and after organ and tissue transplantation, have estab-
lished a population of immunocompromised individuals
prone to reactivation of opportunistic pathogens, including
Toxoplasma gondii, particularly in geographical areas with
a high exposure to this protozoan. In patients with AIDS,
T. gondii has emerged as the leading cause of focal cerebral
lesions, most commonly presenting as toxoplasmic encephal-
itis (TE).1 Since available therapies are unable to eliminate the
parasite from the infected host, treatment of a TE episode
must be followed by life-long maintenance therapy. How-
ever, standard treatment with pyrimethamine and sulfa-
diazine is associated with considerable toxicity, often requiring
discontinuation of the drugs.2,3 Consequently, new therapies
are critically needed. Evaluation of a number of known and
newly developed drugs and drug combinations led to the
concept of combination therapy as the current strategy of
choice for the treatment of toxoplasmosis in this setting.4
The hydroxynaphthoquinone atovaquone (ATO) appears
to be active not only against tachyzoites, but also against
bradyzoite-containing T. gondii cysts.5 Mitochondrial cyto-
chrome b has recently been identified as the target for ATO in
T. gondii.6 ATO has been shown to be effective in animal
models of infection, alone7–10 or combined with other drugs
such as pyrimethamine and sulfadiazine,11 or rifabutin,4,12 and
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is being used increasingly in human therapy.13–15 We have
reported on the synergic activity of ATO and clindamycin
(CLI), a widely used alternative drug16,17 with well-established
anti-T. gondii activity,18–21 in murine toxoplasmosis induced
with the mouse-virulent (type-1) RH strain of T. gondii.22
However, since type-2 strains account for 65% of cases of
reactivation of toxoplasmosis in AIDS,23 in this report we
present data on the anti-T. gondii efficacy of ATO and CLI in
murine infection induced with Me49 as a typical type-2 strain,
including a model of T. gondii recrudescence.
Materials and methods
Mice
Female Swiss-Webster mice (Medical Military Academy
Animal Research Facility, Belgrade, Yugoslavia), 6 weeks
old, weighing 18–22 g at the beginning of experiments, were
used. Mice were housed five or six per cage (depending on the
experiment) and offered drinking water and regular mouse
feed ad libitum, unless otherwise specified. All animal studies
were performed with the approval of a local (Institute for
Medical Research) ethics committee.
Parasites
Brain cysts of the Me49 strain of T. gondii (initially provided
by Dr J. P. Dubey, Beltsville, MD, USA), regularly main-
tained by passage through Swiss-Webster mice twice a year,
were used to establish chronic infection. To obtain cysts for
experimental infections, mice infected at least 8 weeks previ-
ously were killed by asphyxiation in chloroform and their
brains removed and homogenized in a Teflon homogenizer
with 1 mL of saline each. For cyst enumeration, 25 µL of the
brain suspensions was placed on slides and microscopically
counted. The number of cysts per brain was calculated by
multiplying the number counted in four drops by 10, giving a
threshold sensitivity of 10 cysts per brain. For experimental
infections, fresh mice were inoculated by intraoesophageal
gavage with 250 µL brain suspensions assessed to contain
10 or 20 cysts. In our experience, inoculation of 10 cysts
produces consistent infection without mortality, whereas
inoculation of ≥20 cysts results in mortality;24 thus, to allow
for differences in survival after early drug treatment, inocula
of 20 cysts were used to develop acute infection, whereas
10 cysts were inoculated to establish chronic infection.
Drugs
ATO (micronized powder, lot 291604A; GlaxoWellcome,
Stevenage, UK, kindly provided by Dr Simon Lister) was
administered at 5, 25, 50 and 100 mg/kg body weight per day.
CLI (CLI hydrochloride powder, lot 353YS; Upjohn,
supplied by Yusapharm, Belgrade, Yugoslavia) was adminis-
tered at 25, 50 and 400 mg/kg/day.
On the basis of the observation that mice consume 4 g of
food per day,18,20 the desired dosages were obtained by adding
ATO 0.025, 0.125, 0.25 and 0.5 mg and CLI 0.125, 0.25 and
2.0 mg, respectively, per 1 g of ground mouse feed. Fresh food
was supplied daily.
These dosages were selected on the basis of previous
work7,12,18,19,21 as effective (ATO 100 and CLI 400 mg/kg/day)
or, to better reveal the effects of the combined therapy, as
suboptimal (all lower dosages of both drugs).
To control for drug side-effects, in a preliminary experi-
ment, separate groups of mice were given ATO (100 mg/kg/
day) and CLI (400 mg/kg/day) for 3 weeks and ATO+CLI
(100+400 mg/kg/day) for 2 weeks. No clinically significant
toxicity (ruffled fur, lethargy, weight loss) was observed over
a period of 3 months.
Dexamethasone-sodium-phosphate (DXM; ICN Galenika,
Belgrade, Yugoslavia) was given at a dosage of 2.5 mg/kg/
day per mouse, obtained by dissolving 5 mg of DXM per 1 L
of drinking water. Treated and untreated water was changed
three times a week.
Hydrocortisone-21-acetate (CA, lot. 87494; ICN Bio-
medicals, Aurora, OH, USA) was administered at 50 mg/kg
by subcutaneous injection three times a week.
Co-amoxiclav (Panklav; Panfarma, Belgrade, Yugoslavia)
was given in drinking water at 1 g/L for the period of adminis-
tration of DXM and CA to prevent bacterial superinfection.
Experimental design
Acute infection model. Two separate experiments were per-
formed. Groups of mice (n = 15–20) inoculated with 20 cysts
were arbitrarily assigned to treatment with ATO and CLI, as
follows: ATO 100 and CLI 400 mg/kg/day, alone and com-
bined (experiment 1); ATO 25 and CLI 50 mg/kg/day, alone
and combined (experiment 2); or left untreated to serve as
controls. In both experiments, treatment was initiated day 4
post-infection and continued for 14 consecutive days. Mice
were observed for 30 days after the end of treatment, at which
point the survivors were killed and the brains removed and
cysts counted as described above.
Chronic infection model. Groups of mice (n = 15) inoculated
with 10 cysts 3 months previously were arbitrarily assigned
to treatment with ATO 100, CLI 400 and ATO+CLI
100+400 mg/kg/day for 14 consecutive days or left untreated
as controls. Fourteen days after the end of treatment, they
were killed and processed as above.
Model of chronic infection in the immunosuppressed host
(reactivated toxoplasmosis). DXM and CA were used to
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choice of corticoid drug regimens was based on our previous
work,24 which showed that DXM, but not CA alone, induces
immunosuppression leading to recrudescence of T. gondii in
previously latent infection. However, the addition of CA to
DXM potentiates the immunosuppressive effect of DXM.
Clinically manifest disease followed by mortality begins after
2 weeks and continues throughout the period of corticoid
administration. Thus, in experiment 1, groups of mice (n = 12)
inoculated with 10 cysts 3 months previously were arbitrarily
given DXM alone or combined with CA for 3 weeks and then
treated with ATO+CLI 5+25 and 50+50 mg/kg/day for the
next 4 weeks. Immediately after the end of treatment, the
brain cysts were harvested from the survivors. In experiment
2, groups of chronically infected mice (n = 18) were pre-
treated with DXM for 14 days and then arbitrarily given
ATO+CLI 25+50, 50+50 and 100+400 mg/kg/day for 3 weeks.
Five mice from each treatment group were killed immediately
at the end of treatment and examined for brain cyst burdens,
whereas the remaining mice were observed for the next
12 weeks, at which time (day 120 after initiation of immuno-
suppressive treatment) the survivors were killed and pro-
cessed as above.
In all models, mice were monitored daily and deaths were
recorded. In mice dying during the experiments as well as
those surviving the observation period as specified in the
respective model, brain parasite burdens were determined as
described above.
Bioassay
If no cysts were observed in at least four samples of a brain
tissue preparation, the remainder of the brain homogenate
was inoculated by mouth into two fresh mice per sample
(∼450 µL each). Mice were killed after 6 weeks and brain
tissue examined for the presence of brain cysts.
Statistical analysis
Survival rates in particular groups were estimated by the
Kaplan–Meier product limit method and compared by the log
rank (two curves) and multiple sample (three or more curves)
tests. Differences in the numbers of cysts between groups
were examined by Student’s t-test. The level of statistical
significance was P = 0.05.
Results
Acute infection model
The effects of a 2 week course of treatment with ATO and
CLI initiated day 4 post-infection were monitored by 7 week
survival, as well as by the brain cyst burdens at the time of
death or by the end of the observation period. Compared with
the survival in untreated mice of 60% and 65%, respectively,
in experiments 1 and 2 all treated mice survived significantly
better. Treatment with the lowest dosages of the drugs given
alone (ATO 25 and CLI 50 mg/kg/day) protected 93%
(P = 0.043 and 0.047, respectively) of mice, whereas the
higher dosages of each drug alone (ATO 100 and CLI 400 mg/
kg/day), as well as both combinations (ATO+CLI 25+50 and
100+400 mg/kg/day), afforded protection to virtually all mice
(P = 0.003).
Moreover, the treatment clearly reduced the number of
cysts (Figure 1). However, important differences between the
effects of ATO and CLI were observed. Although, com-
pared with untreated mice, the cyst burdens were reduced in
mice treated with CLI, the difference reached significance
(P = 0.027) only in experiment 2. On the other hand, in both
experiments, the cyst burdens in mice treated with ATO both
alone and combined with CLI were significantly lower than in
both untreated mice (P < 0.0001) and mice treated with CLI
alone (P = 0.0002 and 0.0008, respectively, in experiment 1;
and P = 0.0044 and 0.005, respectively, in experiment 2).
However, there were no differences in either experiment
between the effects of ATO both alone and combined with
CLI (P > 0.05).
Interestingly, no brain cysts were observed on direct
examination of the brain tissue in eight treated mice (two
treated with ATO 25, one treated with ATO 100, one treated
with CLI 400, two treated with ATO+CLI 25+50 and two
treated with ATO+CLI 100+400 mg/kg/day). However, sub-
inoculation of these brain homogenates into fresh mice gave
rise to T. gondii cysts in virtually all instances, indicating that
no drug regimen was able to eradicate the infection.
Figure 1. Brain cysts (mean ± S.D.) in mice acutely infected with
20 cysts of the Me49 strain of T. gondii treated with ATO and CLI alone
(100 or 25 and 400 or 50 mg/kg/day, respectively) or combined (AC1
and AC2, 100+400 and 25+50 mg/kg/day, respectively) from day 4 post-
infection for 14 days. Cysts were harvested 7 weeks post-infection. Con-
trol, untreated infected mice. *P < 0.05; **P < 0.01 and ***P < 0.001
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Chronic infection model
In chronically infected mice, which all survived throughout
the experiment whether treated or not, 2 weeks after the end of
a 2 week course of treatment with ATO 100 and CLI 400 mg/
kg/day alone, the cyst burdens were insignificantly (P > 0.05)
decreased, i.e. to 75.9% and 76.4%, respectively, of those
in untreated mice (Figure 2). However, compared with
untreated mice, treatment with ATO combined with CLI
reduced the cyst burden significantly (P = 0.033). Compared
with mice treated with ATO and CLI alone, the cyst burden in
mice treated with the combined drugs was lowered to only
43%; although this difference did not reach significance, it
came close (P = 0.055 and 0.078, respectively).
Model of reactivated toxoplasmosis
In experiment 1, chronically infected mice pre-treated with
DXM alone or combined with CA for 3 weeks were submitted
to a 4 week course of treatment with combinations of
ATO+CLI 5+25 and 50+50 mg/kg/day. All untreated mice
immunosuppressed with both DXM and CA succumbed to
the infection by day 43, whereas 18% of those suppressed
with DXM alone survived the observation period (Figure 3).
Compared with these, mice treated with ATO+CLI 5+25 mg/
kg/day did not survive any better (0% and 18% survival,
respectively, for the DXM+CA and DXM pre-treated groups).
In contrast, treatment at 50+50 mg/kg/day enhanced the sur-
vival of mice on suppressive regimen to 30%. However, the
expected probabilities of survival did not vary significantly
either among all groups taken together (P = 0.2919, multiple
sample test) or between any two groups (P > 0.05). Similarly,
although the cyst burdens (in all mice dying during the
treatment/observation period or survivors killed at the end of
the experiment) (Figure 4) were decreased, compared with
untreated mice on either suppressive regimen, in mice treated
with ATO+CLI 5+25 mg/kg/day by two-fold (to 59.2% and
46.4% of the control values) and even by four-fold in mice
treated with ATO+CLI 50+50 mg/kg/day (to 27.2% and
23.1% of the control values), these differences were not
significant, obviously due to high standard deviations in the
untreated mice. Still, the cyst reduction induced by the higher
dosage combination (50+50 mg/kg/day) in mice on either
suppressive regimen was close to significant compared
with the respective controls (DXM+CA, P = 0.07; DXM,
P = 0.058).
Figure 2. Brain cysts (mean ± S.D.) in mice chronically infected with
10 cysts of the Me49 strain of T. gondii 3 months previously, treated with
ATO and CLI alone (100 and 400 mg/kg/day, respectively) or combined
(100+400 mg/kg/day) for 14 days. Cysts were harvested 2 weeks after
the end of treatment. Ø, control (untreated infected) mice. *P < 0.05
versus control mice.
Figure 3. Effect of a 4 week course of treatment with combinations of
ATO and CLI (5+25 and 50+50 mg/kg/day) on the survival (Kaplan–
Meier estimates) of chronically infected mice immunosuppressed with
DXM alone (open symbols) or combined with CA (filled symbols) for
3 weeks. Chronic infection was established by inoculation of 10 cysts
of the Me49 strain of T. gondii 3 months before immunosuppressive
treatment.
Figure 4. Brain cysts (mean ± S.D.) in chronically infected mice
immunosuppressed with DXM alone or combined with CA for 3 weeks
and treated with combinations of ATO and CLI (5+25 and 50+50 mg/kg/
day) for 4 weeks. Chronic infection was established by inoculation of
10 cysts of the Me49 strain of T. gondii 3 months before immuno-
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Clearly, a 3 week suppression with DXM both alone and
combined with CA induced recrudescence of T. gondii that
was hard to treat, particularly with low dosages of ATO+CLI
(5+25 mg/kg/day) even if administered for as long as 4 weeks.
Since in the acute infection model a good effect of ATO
combined with CLI was shown when the dosage of ATO was
at least 25 mg/kg/day, a final experiment was performed in
which mice pre-treated with DXM for only 2 weeks were
treated with ATO+CLI 25+50, 50+50 and 100+400 mg/kg/
day for 3 weeks. Mice were observed for 120 days after the
beginning of immunosuppressive treatment. Compared with
the 9% survival rate in untreated immunosuppressed mice
(Figure 5), treatment significantly enhanced survival, with
protection rates ranging from 55% to 67%, depending on the
regimen (P < 0.05 for all groups, log rank test). On the other
hand, there were no significant variations either among dif-
ferent treatment groups taken together (P = 0.939, multiple
sample test) or between any two groups (P > 0.05).
Increased survival in mice treated with any of the
ATO+CLI 25+50, 50+50 and 100+400 mg/kg/day regimens
was associated with a significant reduction of the cyst burdens
(taking into account all mice dying during the treatment/
observation period or killed at the end of the experiment)
(Figure 6a) compared with untreated mice (P = 0.017, 0.0001
and 0.0001, respectively). However, comparison of the cyst
burdens between the end of the treatment (day 36) and the end
of the 120 day observation period (Figure 6b) showed that in
mice on each course of treatment the cyst burdens continued
to decrease over time; this decrease was highly significant
with the highest dosage regimen (P = 0.0003). In contrast, the
cyst burdens in the untreated mice increased over time
(P < 0.0001). As a result, the cyst counts in all treated mice,
already reduced at the end of treatment, were seven- to
14-fold lower than in untreated mice by day 120 (P < 0.0001).
This indicates that a short-course (3 week) treatment with com-
binations of ATO and CLI has a long-term (at least 3 month)
effect on renewed cyst formation in immunosuppressed mice.
Discussion
The results presented here clearly demonstrate the anti-T.
gondii activity of the combination of ATO and CLI in murine
infection induced with a mouse-non-virulent (type-2) parasite
Figure 5. Effect of a 3 week course of treatment with combinations of
ATO and CLI (25+50, 50+50 and 100+400 mg/kg/day) on the survival
(Kaplan–Meier estimates) of chronically infected mice immuno-
suppressed with DXM for 2 weeks. Chronic infection was established
by inoculation of 10 T. gondii cysts of the Me49 strain 3 months before
immunosuppressive treatment.
Figure 6. Brain cysts (mean ± S.D.) in chronically infected mice immunosuppressed with DXM for 2 weeks and treated with combinations of
ATO and CLI (AC1, AC2 and AC3, 25+50, 50+50 and 100+400 mg/kg/day, respectively) for 3 weeks in (a) all mice irrespective of the time of
death/sacrifice (*P < 0.05 and ***P < 0.001 versus control mice) and (b) mice killed immediately after treatment (day 36) (white bars) and at the end
of the experiment (day 120) (black bars) (***P < 0.001 between time points). Chronic infection was established by inoculation of 10 cysts of the
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strain. In all models, i.e. in acute, chronic and reactivated
toxoplasmosis, the combined drugs were effective in terms of
both significantly increased survival and decreased brain cyst
burdens compared with no treatment.
In acutely infected mice, however, treatment with com-
binations of ATO and CLI, in addition to protecting 100% of
the mice, significantly reduced the cyst burden compared
with treatment with CLI alone, but not with ATO alone,
indicating that in this model the most effective component of
the combination was ATO. ATO both alone and combined
with CLI greatly reduced the brain cyst burden, which
remained extremely low weeks after treatment, even below
10 in some, as shown by their apparent absence on direct
examination. However, positive bioassays in all such cases
indicate that the drugs appear, at least under the experimental
conditions used (duration of treatment, drug dosages), incap-
able of eradicating the parasite.
On the other hand, in chronically infected mice, ATO
combined with CLI significantly reduced the brain cyst load
compared not only with no treatment but also with either drug
alone. A stronger effect of the combined drugs as opposed to a
similarly insignificant reduction of the parasite burden by
each drug alone, in view of the known activity of ATO against
cysts, probably reflects the natural history of infection with
the Me49 strain; this strain tends continuously to give rise to
new cyst formation, presumably preceded by cyst rupture and
proliferation of tachyzoites that are then converted into
bradyzoites; CLI is active against these tachyzoites, reducing
their number and hence reducing the number of newly formed
cysts.
The discrepancy between the effect of ATO in acute
infection, where it reduced the brain cyst burden comparably
to the combined drugs, and its lower efficacy in 3-month-old
chronic infections, may be explained by ATO being more
effective against metabolically active immature bradyzoites
than against mature ones.8
Most importantly, ATO combined with CLI showed
activity in models of corticoid drug-induced recrudescence of
T. gondii, as shown by significantly increased brain cyst
burdens in immunosuppressed mice. This activity was
dependent directly on the drug dosage and indirectly on the
level of immunosuppression. In immunosuppression induced
by pre-treatment with both DXM and CA, survival was lower
and brain cyst burdens higher than in mice suppressed with
DXM alone. The lowest dosages of the drugs required to
achieve a protective effect were ATO 25 and CLI 50 mg/kg/
day, which is similar to what we had shown in infection
induced with the RH strain of T. gondii.22 Duration of
corticoid drug administration constituted an important vari-
able of the immunosuppressive protocol. Thus, in mice pre-
treated with DXM for 2 and 3 weeks, courses of treatment
with ATO+CLI 50+50 mg/kg/day protected 67% and 30%,
respectively. Therefore, treatment was more likely to reduce
the parasite load below critical levels when initiated after
2 rather than 3 weeks of DXM administration. This is consist-
ent with the reported DXM-induced release of parasites from
pre-existing cysts and new cyst formation as early as after
6–12 days of administration.25 Another important observation
was that, when given at effective dosages, the effects of
combinations of ATO and CLI were long-term, as shown by
the tendency of the brain cyst loads, which increase over time
in untreated mice, to continue decreasing for months after the
end of treatment. Without attempting to speculate on the
underlying reasons, this finding may be of the greatest sig-
nificance from a clinical standpoint.
Even several-fold lower cyst burdens were not always
statistically significant, due, as mentioned, to the wide stand-
ard deviations, which probably reflect the variations in the
number of bradyzoites within initial cysts (between a few and
several hundred),26 and subsequent variability in new cyst
formation.
In conclusion, the demonstrated efficacy of ATO com-
bined with CLI in murine infection with a cystogenic strain of
T. gondii, taken together with our previous findings of syn-
ergic activity of the same drug combination against infection
induced with the RH strain, clearly shows the anti-T. gondii
potential of this drug combination. In as much as findings in
animal models may be extrapolated to the human situation,
given that ATO is generally well tolerated13,14 and, moreover,
that in combination the drugs may be used at dosages lower
than when used alone, which may reduce the rare adverse
side-effects of CLI,16,17 the combination of ATO and CLI may
offer an efficient yet safe alternative for the treatment of toxo-
plasmosis in both immunocompetent and immunosuppressed
individuals, something that warrants clinical evaluation.
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